Compare SON & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | LEGN |
|---|---|---|
| Founded | 1899 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.9B |
| IPO Year | 2014 | 2020 |
| Metric | SON | LEGN |
|---|---|---|
| Price | $50.68 | $27.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $60.13 | ★ $61.33 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 510.30 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $7,518,753,000.00 | N/A |
| Revenue This Year | $0.10 | $42.68 |
| Revenue Next Year | $1.82 | $30.52 |
| P/E Ratio | $74.32 | ★ N/A |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $16.24 |
| 52 Week High | $58.44 | $45.30 |
| Indicator | SON | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 43.10 |
| Support Level | $46.19 | $23.10 |
| Resistance Level | $52.71 | $28.70 |
| Average True Range (ATR) | 1.51 | 2.86 |
| MACD | 0.36 | -0.55 |
| Stochastic Oscillator | 72.95 | 24.59 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.